IS7570A - Notkun á CETP lötum og mögulega HMG COA redúktasalötum og/eða miðlum gegn háþrýstingi - Google Patents

Notkun á CETP lötum og mögulega HMG COA redúktasalötum og/eða miðlum gegn háþrýstingi

Info

Publication number: IS7570A
Authority: IS; Iceland
Prior art keywords: possibly; salts; coa reductase; hmg coa; cetp inhibitors
Prior art date: 2002-07-02

Application number

IS7570A

Other languages

English (en)

Inventor

Trung Nguyen Tu

Lester Shear Charles

Harold Revkin James

Benjamin Ruggeri Roger

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-07-02

Filing date

2004-11-29

Publication date

2004-11-29

2004-11-29 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2004-11-29 Publication of IS7570A publication Critical patent/IS7570A/is

Links

102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 title 1
108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 title 1
239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 title 1
239000005555 hypertensive agent Substances 0.000 title 1
150000003839 salts Chemical class 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Immunology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Reproductive Health (AREA)
Transplantation (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Biochemistry (AREA)
Ophthalmology & Optometry (AREA)
Pulmonology (AREA)
Tropical Medicine & Parasitology (AREA)

IS7570A 2002-07-02 2004-11-29 Notkun á CETP lötum og mögulega HMG COA redúktasalötum og/eða miðlum gegn háþrýstingi IS7570A (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US39339502P	2002-07-02	2002-07-02
PCT/IB2003/002792 WO2004004778A1 (en)	2002-07-02	2003-06-18	Use of cetp inhibitors and optionally hmg coa reductable inhibitors and/or antihypertensive agents

Publications (1)

Publication Number	Publication Date
IS7570A true IS7570A (is)	2004-11-29

Family

ID=30115572

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS7570A IS7570A (is)	2002-07-02	2004-11-29	Notkun á CETP lötum og mögulega HMG COA redúktasalötum og/eða miðlum gegn háþrýstingi

Country Status (23)

Country	Link
US (1)	US20040053842A1 (is)
EP (1)	EP1519754A1 (is)
JP (1)	JP2005532388A (is)
KR (1)	KR20050025578A (is)
CN (1)	CN1665537A (is)
AP (1)	AP2004003189A0 (is)
AU (1)	AU2003244921A1 (is)
BR (1)	BR0312421A (is)
CA (1)	CA2488736A1 (is)
EA (1)	EA200401471A1 (is)
EC (1)	ECSP045520A (is)
HR (1)	HRP20041238A2 (is)
IL (1)	IL165328A0 (is)
IS (1)	IS7570A (is)
MA (1)	MA27311A1 (is)
MX (1)	MXPA05000015A (is)
NO (1)	NO20050497L (is)
OA (1)	OA12876A (is)
PL (1)	PL374878A1 (is)
TN (1)	TNSN04268A1 (is)
TW (1)	TW200401768A (is)
WO (1)	WO2004004778A1 (is)
ZA (1)	ZA200409582B (is)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7071210B2 (en) *	2002-07-02	2006-07-04	Pfizer Inc.	CETP inhibitors in combination with antihypertensive agents and uses thereof
WO2004056359A1 (en) *	2002-12-20	2004-07-08	Pfizer Products Inc.	Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
US20040132771A1 (en) *	2002-12-20	2004-07-08	Pfizer Inc	Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
EP1961419B1 (en) *	2002-12-20	2010-03-24	Pfizer Products Inc.	Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor
CN102558155A (zh)	2003-01-14	2012-07-11	阿伦纳药品公司	作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
AU2004222436A1 (en) *	2003-03-17	2004-09-30	Japan Tobacco Inc.	Method for increasing the oral bioavailability of S-(2-(((1- (2-ethylbutyl) cyclohexyl)carbonyl) amino) phenyl)-2-methylpropanethioate
PT1603553E (pt) *	2003-03-17	2012-02-03	Japan Tobacco Inc	Composições farmacêuticas de inibidores de cetp
TWI494102B (zh) *	2003-05-02	2015-08-01	Japan Tobacco Inc	包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
CN1812983A (zh) *	2003-05-30	2006-08-02	兰贝克赛实验室有限公司	取代的吡咯衍生物及其作为hmg－co抑制剂的用途
TWI335328B (en)	2003-07-14	2011-01-01	Arena Pharm Inc	Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related hereto
MXPA06006831A (es) *	2003-12-16	2006-08-23	Novartis Ag	Uso de estatinas para el tratamiento del sindrome metabolico.
CA2561564A1 (en) *	2004-04-07	2005-10-27	Millennium Pharmaceuticals, Inc.	Pgd2 receptor antagonists for the treatment of inflammatory diseases
US20060063803A1 (en) *	2004-09-23	2006-03-23	Pfizer Inc	4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
WO2007115131A2 (en) *	2006-03-29	2007-10-11	Guilford F Timothy	Liposomal reduced glutathione and 1-arginine, including other ingredient(s)
WO2006054308A2 (en) *	2004-11-22	2006-05-26	Dexcel Pharma Technologies Ltd.	Stable atorvastatin formulations
MX2007006777A (es) *	2004-12-06	2007-08-06	Avigen Inc	Ibudilast para tratar dolor neuropatico y sindromes asociados.
WO2006069162A1 (en) *	2004-12-20	2006-06-29	Reddy Us Therapeutics, Inc.	Novel heterocyclic compounds and their pharmaceutical compositions
EP1833466A1 (en) *	2004-12-28	2007-09-19	Ranbaxy Laboratories Limited	Methods for the preparation of stable pharmaceutical solid dosage forms of atorvastatin and amlodipine
US8604055B2 (en) *	2004-12-31	2013-12-10	Dr. Reddy's Laboratories Ltd.	Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
DK1848430T3 (da)	2004-12-31	2017-11-06	Dr Reddys Laboratories Ltd	Nye benzylamin-derivativer som cetp-inhibitors
MY148521A (en)	2005-01-10	2013-04-30	Arena Pharm Inc	Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
WO2007106111A2 (en) *	2005-07-01	2007-09-20	Elan Pharma International Limited	Nanoparticulate and controlled release compositions comprising nilvadipine
US20090162316A1 (en)	2005-07-05	2009-06-25	Harvard University	Liver targeted conjugates
SG166829A1 (en) *	2005-11-08	2010-12-29	Ranbaxy Lab Ltd	Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
WO2008020314A2 (en) *	2006-03-14	2008-02-21	Ranbaxy Laboratories Limited	Statin stabilizing dosage formulations
WO2007116243A2 (en) *	2006-04-10	2007-10-18	Mintails Limited	Method for treating fibromyalgia and related conditions
WO2008010087A2 (en) *	2006-07-14	2008-01-24	Ranbaxy Laboratories Limited	Polymorphic forms of an hmg-coa reductase inhibitor and uses thereof
EP2131841B1 (en) *	2007-01-30	2012-08-01	Avigen, Inc.	Methods for treating acute pain
WO2008137012A1 (en) *	2007-05-03	2008-11-13	Avigen, Inc.	Use of a glial attenuator to prevent amplified pain responses caused by glial priming
US20090074740A1 (en) *	2007-05-14	2009-03-19	Noah Berkowitz	Use of haptoglobin genotyping in diagnosis and treatment of defective reverse cholesterol transport (RCT)
WO2009021113A1 (en) *	2007-08-09	2009-02-12	Holtzman, Jordan, L.	Methods for enhancing glutahione peroxidase activity
EP2070520A1 (en) *	2007-12-11	2009-06-17	LEK Pharmaceuticals D.D.	Pharmaceutical composition comprising at least one active agent and a binder, which swells in an acidic media
WO2012046681A1 (ja) *	2010-10-04	2012-04-12	興和株式会社	脂質代謝関連ｍＲＮＡの発現抑制剤
MX2013003184A (es)	2010-09-22	2013-06-07	Arena Pharm Inc	Moduladores del receptor gpr119 y el tratamiento de transtornos relacionados con el mismo.
CA2845284C (en)	2011-08-18	2018-03-06	Dr. Reddy's Laboratories Ltd.	Substituted heterocyclic amine compounds as cholesteryl ester-transfer protein (cetp) inhibitors
JP6140168B2 (ja)	2011-09-27	2017-05-31	ドクターレディズラボラトリーズリミテッド	アテローム性動脈硬化症の処置のために有用なコレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての５−ベンジルアミノメチル−６−アミノピラゾロ［３，４−ｂ］ピリジン誘導体
EP3185869A1 (en) *	2014-08-28	2017-07-05	Dezima Pharma B.V.	PHARMACEUTICAL COMPOSITION AND THERAPEUTIC COMBINATION COMPRISING A CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR AND HMG CoA REDUCTASE INHIBITORS
AU2016205361C1 (en)	2015-01-06	2021-04-08	Arena Pharmaceuticals, Inc.	Methods of treating conditions related to the S1P1 receptor
PL3310760T3 (pl)	2015-06-22	2023-03-06	Arena Pharmaceuticals, Inc.	Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
WO2018019911A1 (en) *	2016-07-27	2018-02-01	Hartis-Pharma Sarl	Therapeutic combinations to treat red blood cell disorders
KR20190116416A (ko)	2017-02-16	2019-10-14	아레나 파마슈티칼스, 인크.	원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
AU2019280822A1 (en)	2018-06-06	2021-01-07	Arena Pharmaceuticals, Inc.	Methods of treating conditions related to the S1P1 receptor
CN116196314B (zh) *	2023-05-04	2023-08-15	广州市妇女儿童医疗中心	Ri-1或其盐在制备防治胃肠道疾病的药物中的应用
EP4566597A1 (en) *	2023-12-05	2025-06-11	Hospital Clínic de Barcelona	Statins useful in the treatment of splachnic vascular dysfunctions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6144790A (en) *	1997-02-07	2000-11-07	Bledin; Anthony G	Contact fiber optic impact sensor
GT199800127A (es) *	1997-08-29	2000-02-01		Combinaciones terapeuticas.
GT199800126A (es) *	1997-08-29	2000-01-29		Terapia de combinacion.
TR200000562T2 (tr) *	1997-08-29	2000-08-21	Pfizer Products Inc.	Amlodifin ve bir statin bileşiği içeren bileşim terapisi
US6147089A (en) *	1998-09-17	2000-11-14	Pfizer Inc.	Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
GT199900147A (es) *	1998-09-17	1999-09-06		1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6147090A (en) *	1998-09-17	2000-11-14	Pfizer Inc.	4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6140342A (en) *	1998-09-17	2000-10-31	Pfizer Inc.	Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6197786B1 (en) *	1998-09-17	2001-03-06	Pfizer Inc	4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
HN2000000050A (es) *	1999-05-27	2001-02-02	Pfizer Prod Inc	Sal mutua de amlodipino y atorvastatina
BR0011006A (pt) *	1999-05-27	2002-02-19	Pfizer Prod Inc	Prõ-drogas mútuas de amlodipina e atorvastatina
US20030092745A1 (en) *	2000-02-25	2003-05-15	Pfizer Inc.	Combination therapy
US20020013334A1 (en) *	2000-06-15	2002-01-31	Robl Jeffrey A.	HMG-CoA reductase inhibitors and method
CN1735416A (zh) *	2000-08-15	2006-02-15	辉瑞产品公司	治疗剂组合
US6737430B2 (en) *	2000-11-09	2004-05-18	Pfizer, Inc.	Mutual prodrug of amlodipine and atorvastatin
US20030064967A1 (en) *	2001-04-11	2003-04-03	Jayraz Luchoomun	Methods to increase plasma HDL cholesterol levels and improve HDL functionality with probucol monoesters
US7071210B2 (en) *	2002-07-02	2006-07-04	Pfizer Inc.	CETP inhibitors in combination with antihypertensive agents and uses thereof

2003
- 2003-06-10 US US10/459,683 patent/US20040053842A1/en not_active Abandoned
- 2003-06-18 BR BR0312421-5A patent/BR0312421A/pt not_active IP Right Cessation
- 2003-06-18 EP EP03738394A patent/EP1519754A1/en not_active Withdrawn
- 2003-06-18 OA OA1200400342A patent/OA12876A/en unknown
- 2003-06-18 KR KR1020057000061A patent/KR20050025578A/ko not_active Ceased
- 2003-06-18 HR HR20041238A patent/HRP20041238A2/xx not_active Application Discontinuation
- 2003-06-18 CN CN038155753A patent/CN1665537A/zh active Pending
- 2003-06-18 PL PL03374878A patent/PL374878A1/xx not_active Application Discontinuation
- 2003-06-18 WO PCT/IB2003/002792 patent/WO2004004778A1/en not_active Ceased
- 2003-06-18 AP AP2004003189A patent/AP2004003189A0/xx unknown
- 2003-06-18 EA EA200401471A patent/EA200401471A1/ru unknown
- 2003-06-18 JP JP2004519080A patent/JP2005532388A/ja not_active Withdrawn
- 2003-06-18 CA CA002488736A patent/CA2488736A1/en not_active Abandoned
- 2003-06-18 IL IL16532803A patent/IL165328A0/xx unknown
- 2003-06-18 MX MXPA05000015A patent/MXPA05000015A/es not_active Application Discontinuation
- 2003-06-18 AU AU2003244921A patent/AU2003244921A1/en not_active Abandoned
- 2003-07-01 TW TW092117985A patent/TW200401768A/zh unknown
2004
- 2004-11-26 ZA ZA200409582A patent/ZA200409582B/en unknown
- 2004-11-29 IS IS7570A patent/IS7570A/is unknown
- 2004-12-17 MA MA28016A patent/MA27311A1/fr unknown
- 2004-12-30 EC EC2004005520A patent/ECSP045520A/es unknown
- 2004-12-30 TN TNP2004000268A patent/TNSN04268A1/fr unknown
2005
- 2005-01-28 NO NO20050497A patent/NO20050497L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
HRP20041238A2 (en)	2005-06-30
MXPA05000015A (es)	2005-04-08
OA12876A (en)	2006-09-15
TW200401768A (en)	2004-02-01
KR20050025578A (ko)	2005-03-14
ZA200409582B (en)	2006-08-30
CA2488736A1 (en)	2004-01-15
TNSN04268A1 (fr)	2007-03-12
CN1665537A (zh)	2005-09-07
NO20050497L (no)	2005-03-08
AP2004003189A0 (en)	2004-12-31
IL165328A0 (en)	2006-01-15
AU2003244921A1 (en)	2004-01-23
EP1519754A1 (en)	2005-04-06
WO2004004778A1 (en)	2004-01-15
PL374878A1 (en)	2005-11-14
BR0312421A (pt)	2005-04-19
JP2005532388A (ja)	2005-10-27
US20040053842A1 (en)	2004-03-18
MA27311A1 (fr)	2005-05-02
ECSP045520A (es)	2005-03-10
EA200401471A1 (ru)	2005-06-30

Publication	Publication Date	Title
IL165328A0 (en)	2006-01-15	Use of cetp inhibitors and optionally hmg coa reductase inhibitors and/or antihypertensive agents
NO20026012D0 (no)	2002-12-13	HMG-CoA-reduktase-inhibitorer og metode
NO20026011D0 (no)	2002-12-13	HMG-CoA-reduktase-inhibitorer og fremgangsmåte
PL374364A1 (en)	2005-10-17	Use of cetp inhibitors and antihypertensive agents as well as optionally hmg coa reductase inhibitors
ATE286049T1 (de)	2005-01-15	Pyridazinonaldose reductase inhibitoren
NO20014823D0 (no)	2001-10-04	Heterocyklus-holdige bifenyl-aP2-inhibitorer og metode
ATE302193T1 (de)	2005-09-15	Benzoheterozyklen und ihre verwendung als mek inhibitoren
DE60103974D1 (de)	2004-07-29	Gyrase-inhibitoren und ihre verwendung
IL173936A0 (en)	2006-07-05	Heterocyclic inhibitors of mek and methods of use thereof
NO20033197D0 (no)	2003-07-15	Fremgangsmåte og leggeskip for spolerörlegging
EP1507756A4 (en)	2006-03-15	CCR9 INHIBITORS AND USE THEREOF
DE60319430D1 (de)	2008-04-10	R- und fgfr-inhibitoren
NO20032668L (no)	2003-06-12	Gyraseinhibitorer og anvendelser derav
EP1483597A4 (en)	2006-03-22	NOM SPACE PRESENCE AND INTERCONNECTION TRACKING TECHNIQUES
DK1527050T3 (da)	2010-07-19	Quinolin-derivater og deres anvendelse som mycobakterielle inhibitorer
NO20052779D0 (no)	2005-06-08	Doseringsformer omfattende en CETP-inhibitor og en HMG-CoA-reduktaseinhibitor.
EP1504429A4 (en)	2006-05-03	MONITORING SYSTEM AND ASSOCIATED METHOD
DK1765793T3 (da)	2013-01-14	Anacetrapib og andre cetp-inhibitorer
NO20033387L (no)	2003-09-25	Modifiserte antistoffer og fremgangsmåter for anvendelse
ATE370938T1 (de)	2007-09-15	Pro-pharmakon von cox-2-inhibitoren
NO20052139L (no)	2004-12-23	Bandasje og epidermal posisjoneringsmekanisme og fremgangsmate for anvendelse av samme
IS7792A (is)	2005-04-11	Hýdantóínafleiður og notkun þeirra sem TACE hemla
IS6477A (is)	2002-07-19	Afleiður piperazíns og piperadíns
FI20012528L (fi)	2003-06-21	Menetelmä ja laite radan reunan seurantaan
NO20033854D0 (no)	2003-09-01	N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse